Skip to main content
NCBI home page
Public Health Reports logoLink to Public Health Reports
. 2005 Mar-Apr;120(2):157–164. doi: 10.1177/003335490512000209

A population-based analysis of pneumococcal disease mortality in California, 1989-1998.

Matthew D Redelings 1, Frank Sorvillo 1, Paul Simon 1
PMCID: PMC1497698  PMID: 15842117

Abstract

OBJECTIVES: Pneumococcal disease is an important cause of vaccine-preventable mortality. It is important to understand the burden and distribution of mortality so that prevention efforts can be targeted appropriately. This study evaluated pneumococcal disease mortality and its demographic correlates in California from 1989 to 1998. METHODS: Deaths due to pneumococcal disease were identified from statewide vital records data using multiple cause-coded information. Denominator data were obtained from estimates from the California Department of Finance. Crude and age-adjusted mortality rates and 95% confidence intervals were calculated for each age, gender, and racial/ethnic group. RESULTS: The age-adjusted pneumococcal disease mortality rate was 2.05 deaths per 100,000 population. Mortality was highest in elderly individuals (reaching 38.29 deaths per 100,000 population in individuals older than age 85). Age-adjusted mortality rates were elevated in the African American race/ethnicity group (2.96 deaths per 100,000 population) and males (2.67 deaths per 100,000 population). The majority of individuals who died of pneumococcal disease (78.9%) fell into at-risk groups indicated for vaccination. The majority of all pneumococcal deaths were caused by pneumococcal pneumonia. Mortality was seasonal, reaching a peak in the winter months. A decreasing trend in mortality was observed over the 10-year period examined. CONCLUSIONS: Pneumococcal disease remains a significant cause of vaccine-preventable mortality in the California population. Greater efforts must be made to vaccinate at-risk individuals, especially those in demographic groups at highest risk of death.

Full Text

The Full Text of this article is available as a PDF (125.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amendola A., Tanzi E., Zappa A., Colzani D., Boschini A., Musher D. M., Zanetti A. R. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine. 2002 Nov 1;20(31-32):3720–3724. doi: 10.1016/s0264-410x(02)00357-2. [DOI] [PubMed] [Google Scholar]
  2. Anderson R. N., Rosenberg H. M. Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep. 1998 Oct 7;47(3):1-16, 20. [PubMed] [Google Scholar]
  3. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J. R., Elvin L., Ensor K. M., Hackell J., Siber G. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000 Mar;19(3):187–195. doi: 10.1097/00006454-200003000-00003. [DOI] [PubMed] [Google Scholar]
  4. Black Steven B., Shinefield Henry R., Ling Stella, Hansen John, Fireman Bruce, Spring David, Noyes Jack, Lewis Edwin, Ray Paula, Lee Janelle. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002 Sep;21(9):810–815. doi: 10.1097/00006454-200209000-00005. [DOI] [PubMed] [Google Scholar]
  5. Breiman R. F., Keller D. W., Phelan M. A., Sniadack D. H., Stephens D. S., Rimland D., Farley M. M., Schuchat A., Reingold A. L. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med. 2000 Sep 25;160(17):2633–2638. doi: 10.1001/archinte.160.17.2633. [DOI] [PubMed] [Google Scholar]
  6. Brueggemann Angela B., Coffman Stacy L., Rhomberg Paul, Huynh Holly, Almer Laurel, Nilius Angela, Flamm Robert, Doern Gary V. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother. 2002 Mar;46(3):680–688. doi: 10.1128/AAC.46.3.680-688.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Caetano Raul, Cunradi Carol. Alcohol dependence: a public health perspective. Addiction. 2002 Jun;97(6):633–645. doi: 10.1046/j.1360-0443.2002.00184.x. [DOI] [PubMed] [Google Scholar]
  8. Chamblee R. F., Evans M. C. New dimensions in cause of death statistics. Am J Public Health. 1982 Nov;72(11):1265–1270. doi: 10.2105/ajph.72.11.1265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Comstock G. W., Markush R. E. Further comments on problems in death certification. Am J Epidemiol. 1986 Aug;124(2):180–181. doi: 10.1093/oxfordjournals.aje.a114376. [DOI] [PubMed] [Google Scholar]
  10. Feikin D. R., Schuchat A., Kolczak M., Barrett N. L., Harrison L. H., Lefkowitz L., McGeer A., Farley M. M., Vugia D. J., Lexau C. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000 Feb;90(2):223–229. doi: 10.2105/ajph.90.2.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Inungu J. N., Mokotoff E. D., Kent J. B. Characteristics of HIV infection in patients fifty years or older in Michigan. AIDS Patient Care STDS. 2001 Nov;15(11):567–573. doi: 10.1089/108729101753287658. [DOI] [PubMed] [Google Scholar]
  12. Israel R. A., Rosenberg H. M., Curtin L. R. Analytical potential for multiple cause-of-death data. Am J Epidemiol. 1986 Aug;124(2):161–179. doi: 10.1093/oxfordjournals.aje.a114375. [DOI] [PubMed] [Google Scholar]
  13. Janoff E. N., Tasker S. A., Stevenson M., Rubins J. B., O'Brien J., Utz G., Weiss P., Hall F. W., Wallace M. R. Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. AIDS Res Hum Retroviruses. 1999 Jun 10;15(9):837–845. doi: 10.1089/088922299310746. [DOI] [PubMed] [Google Scholar]
  14. Kroon F. P., van Dissel J. T., Ravensbergen E., Nibbering P. H., van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine. 1999 Oct 14;18(5-6):524–530. doi: 10.1016/s0264-410x(99)00240-6. [DOI] [PubMed] [Google Scholar]
  15. Kyaw M. H., Clarke S., Jones I. G., Campbell H. Incidence of invasive pneumococcal disease in Scotland, 1988-99. Epidemiol Infect. 2002 Apr;128(2):139–147. [PMC free article] [PubMed] [Google Scholar]
  16. Lonks J. R., Garau J., Medeiros A. A. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother. 2002 Dec;50 (Suppl S2):87–92. doi: 10.1093/jac/dkf512. [DOI] [PubMed] [Google Scholar]
  17. Nuorti J. P., Butler J. C., Farley M. M., Harrison L. H., McGeer A., Kolczak M. S., Breiman R. F. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000 Mar 9;342(10):681–689. doi: 10.1056/NEJM200003093421002. [DOI] [PubMed] [Google Scholar]
  18. Nuorti J. P., Butler J. C., Gelling L., Kool J. L., Reingold A. L., Vugia D. J. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med. 2000 Feb 1;132(3):182–190. doi: 10.7326/0003-4819-132-3-200002010-00003. [DOI] [PubMed] [Google Scholar]
  19. O'Brien K. L., Walters M. I., Sellman J., Quinlisk P., Regnery H., Schwartz B., Dowell S. F. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis. 2000 May 18;30(5):784–789. doi: 10.1086/313772. [DOI] [PubMed] [Google Scholar]
  20. Opstelten W., Hak E., Verheij T. J., van Essen G. A. Introducing a pneumococcal vaccine to an existing influenza immunization program: vaccination rates and predictors of noncompliance. Am J Med. 2001 Oct 15;111(6):474–479. doi: 10.1016/s0002-9343(01)00880-4. [DOI] [PubMed] [Google Scholar]
  21. Ortqvist A., Hedlund J., Burman L. A., Elbel E., Höfer M., Leinonen M., Lindblad I., Sundelöf B., Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998 Feb 7;351(9100):399–403. doi: 10.1016/s0140-6736(97)07358-3. [DOI] [PubMed] [Google Scholar]
  22. Robinson K. A., Baughman W., Rothrock G., Barrett N. L., Pass M., Lexau C., Damaske B., Stefonek K., Barnes B., Patterson J. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA. 2001 Apr 4;285(13):1729–1735. doi: 10.1001/jama.285.13.1729. [DOI] [PubMed] [Google Scholar]
  23. Rubins J. B., Janoff E. N. Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs Aging. 2001;18(5):305–311. doi: 10.2165/00002512-200118050-00001. [DOI] [PubMed] [Google Scholar]
  24. Schuchat A., Robinson K., Wenger J. D., Harrison L. H., Farley M., Reingold A. L., Lefkowitz L., Perkins B. A. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med. 1997 Oct 2;337(14):970–976. doi: 10.1056/NEJM199710023371404. [DOI] [PubMed] [Google Scholar]
  25. Schutze Gordon E., Mason Edward O., Jr, Barson William J., Kim Kwang Sik, Wald Ellen R., Givner Laurence B., Tan Tina Q., Bradley John S., Yogev Ram, Kaplan Sheldon L. Invasive pneumococcal infections in children with asplenia. Pediatr Infect Dis J. 2002 Apr;21(4):278–282. doi: 10.1097/00006454-200204000-00004. [DOI] [PubMed] [Google Scholar]
  26. Shapiro E. D., Berg A. T., Austrian R., Schroeder D., Parcells V., Margolis A., Adair R. K., Clemens J. D. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991 Nov 21;325(21):1453–1460. doi: 10.1056/NEJM199111213252101. [DOI] [PubMed] [Google Scholar]
  27. Shenson D., Quinley J., DiMartino D., Stumpf P., Caldwell M., Lee T. Pneumococcal immunizations at flu clinics: the impact of community-wide outreach. J Community Health. 2001 Jun;26(3):191–201. doi: 10.1023/a:1010321128990. [DOI] [PubMed] [Google Scholar]
  28. Sims R. V., Steinmann W. C., McConville J. H., King L. R., Zwick W. C., Schwartz J. S. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med. 1988 May;108(5):653–657. doi: 10.7326/0003-4819-108-5-653. [DOI] [PubMed] [Google Scholar]
  29. Whitney C. G., Farley M. M., Hadler J., Harrison L. H., Lexau C., Reingold A., Lefkowitz L., Cieslak P. R., Cetron M., Zell E. R. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000 Dec 28;343(26):1917–1924. doi: 10.1056/NEJM200012283432603. [DOI] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES